SlideShare a Scribd company logo
Presented By:-
Sweety George
 Hepatitis is a medical condition defined by
the inflammation of the liver and
characeterised by the presence of
inflammatory cells in the tissue of the
organ.
 The condition can be self-limiting or can be
progress to fibrosis and cirrhosis.
 The most common causes of viral hepatitis are the
five unrelated hepatotropic viruses Hepatitis
A, Hepatitis B, Hepatitis C, Hepatitis D,
and Hepatitis E.
 In addition to the nominal hepatitis viruses, other
viruses that can also cause liver inflammation
include Herpes simplex, Cytomegalovirus, Epstein–
Barr virus, or Yellow fever.
 DARK URINE
 Abdominal discomfort
 Right upper abdominal pain
 Jaundice
 Fever
 Nausea
 Anorexia
 Diaherrea
 Fatigue
 Hepatomegalin
 Elevated level of bilirubin
 Hepatitis A (formerly known as “infectious”
hepatitis) is an acute infectious disease
caused by Hepatitis A virus (HAV).
 The disease is heralded by non-specific
symptoms such as fever, chills, headache,
fatigue, generalized weakness and aches
and pains, followed by anorexia, nausea,
vomiting, dark urine and jaundice.
 The disease is benign with complete
recovery in several weeks.
Agent factors
a) AGENT: The causative
agent, the hepatitis A
virus, is an enterovirus of
the Picornaviridae family. It
multiplies only in
hepatocytes.
b) RESISTANCE: The virus is
fairly resistant to heat and
chemicals.
.
RNA
Naked RNA virus
c) RESERVOIR OF INFECTION: The human cases are
the only reservoir of infection.
d) INFECTIVE MATERIAL : Mainly man’s faeces.
a) AGE: Infection with HAV is more frequent
among children than in adults. However,
people from all ages may be infected if
susceptible.
b) SEX: Both sexes are equally susceptible.
Host factors
Incubation period
10-50 days (usually 25 to 30 days)
 Mode of Transmission
a) FAECAL-ORAL ROUTE:
-By contaminated water, food
b) PARENTERAL ROUTE (Rarely):
-By blood and blood products or by
skin penetration through
contaminated needles.
c) SEXUAL TRANSMISSION:
PHYSICAL EXAMINATION
 Icteric sclera,skin and secretions
 Mild weight loss of 2-5kg
 Hepatomegaly.
LABORATORY EXAMINATION
1.Demonstration of Virus in feaces, blood, bile:
By: Immunoelectron microscopy
2. Detection of Antibody :By ELISA
4. Biochemical tests:
i) Alanine aminotransferase (ALT)
ii) Bilirubin
Prevention:-
-hygienic measures and sanitation
-Immunoglobulin to prevent Hepatitis A
Immunoglobin provides protection against
HAV by passive transfer of conc antibodies against
HAV.Ig is effective.preganancy and lactation are not
contraindications to receiving Ig.Given iv and im.
-vaccines
Given as a 2-dose series,6 mnths apart. A vaccine is
useful in preventing secondary infection.
Treatment:
-nospecific, dietary food and long rest
Corticosteroid given in patients with acute HAV
when cholestic or fulminant hepatic failure is
evident.
Hepatitis B
Hepatitis B (formerly known as “serum” hepatitis)
is an acute systemic infection with major
pathology
in the liver, caused by hepatitis B virus.
The acute illness causes liver inflammation,
vomiting,jaundice, and, rarely, death.
Chronic hepatitis B may eventually
cause cirrhosis and liver cancer.
Epidemiology Determinants
Agent factor
a) AGENT: Hepatitis B Virus (HBV)
-It replicates in liver cell.
b) RESERVOIR OF INFECTION:
-Men is the only reservoir of infection which can be
spread either from carriers or from cases.
c) Infective material:
-Contaminated blood is the main source,
-Virus has been found in body secretion such as
saliva, vaginal secretion & Semen in infected
material.
• Mode of transmission
• Parentral route
• Perinatal transmission-spread of infection from HBV
carrier mother to their babies.HBV can infect the
foetus in utero.This rarely occur at birth,as result of
leak of maternal blood into baby’s circulation.
• Sexual transmission.
 Serology
 Liver Chemistry tests
AST, ALT, ALP, and total Bilirubin
 Histology--Immunoperoxidase
staining
 Liver Biopsy--to determine
grade(Inflammation) and
stage(Fibrosis) in chronic
Hepatitis
Prevention
 Vaccination
 - highly effective recombinant vaccines
 Hepatitis B Immunoglobulin (HBIG)
 -exposed within 48 hours of the incident/
neonates whose mothers are HBsAg and HBeAg
positive.
 Other measures
 -screening of blood donors, blood and body
fluid precautions.
National Immunization Schedule
Vaccine When to
Give
Dose Route Site
Hepatitis
B
At birth or
as soon as
possible
with in 24
hours.
0.5 ml IM Antero
lateral
side of
mid thigh
Hepatitis
B 1,2,3
At 6, 10,
14 weeks
0.5 ml IM Antero
lateral
side of
mid thigh
TREATMENT FOR HEPATITIS B?
Alpha interferon and peginterferon,
which slow the replication of the virus
in the body and also boost the immune
system, and the antiviral drugs
lamivudine, adefovir,, entecavir.
Hepatitis C
 Hepatitis C is an infectious disease affecting
primarily the liver, caused by the hepatitis C
virus (HCV).
 The infection is often asymptomatic, but
chronic infection can lead to scarring of the
liver and ultimately to cirrhosis, which is
generally apparent after many years.
Incubation Period
40-120 days
Mode of Transmission
 Intravenous Drug Use
 Healthcare Exposure: Blood Transfusion, transfusion of Blood
products,
Organ Transplant without HCV screening carry significant risk of
infection.
 Hemodialysis
 Accidental injuries with needles/sharps
 Multiple sex partners
 Vertical Transmission: Vertical transmission of hepatitis C from an
infected mother to her child.
• HCV antibody – ELISA used to diagnose hepatitis
C infection. Not useful in the acute phase as it
takes at least 4 weeks after infection before
antibody appears.
• HCV-RNA - various techniques are available e.g.
PCR and branched DNA. May be used to
diagnose HCV infection in the acute phase.
However, its main use is in monitoring the
response to antiviral therapy.
• HCV-antigen - It is used in the same capacity as
HCV-RNA tests but is much easier to carry out.
Diagnosis
Prevention
 Only General Prophylaxis, such as blood, tissue, organ
screening, is possible.
 No specific active or passive immunizing agent is available.
Treatment
 Interferon - may be considered for patients with
chronic active hepatitis.
 Ribavirin - combination of interferon and ribavirin
is more effective than interferon alone.
Hepatitis D
 Hepatitis D, also referred to as hepatitis D
virus (HDV) and classified as Hepatitis delta virus,
is a disease caused by a small circular
enveloped RNA virus.
 HDV infection develops only in patients who are
positive for hepatitis B surface antigen.
Incubation Period
2-12weeks
The primary route of Transmission are believed to
be similar to those of HBV, It can be transmitted
sexually..perinatal transmission is rare.
 Mode of Transmission
 HDV replicates only in liver cell and so the
cellular damage associated with HDV
infection involves mainly in liver.
 HDV co-infection with HBV may be associated
with increased risk of severe clinical
hepatitis,fulminant hepatic failure,chronic
liver disease,cirrhosis and hepatocellular
carcinoma.
Diagnosis
 Delta antigen is primarily expressed in liver
cell nuclei, where it can be demonstrated by
immunofluorescence.
 Anti-delta antibodies appear in serum and
can be identified by ELISA.
IgM antibody appears 2-3 weeks after
infection and is soon replaced by the IgG
antibody in acute delta infection.
TREATMENT
 Interferon
 Lamivudine
 Adefovir
 HBV-HDV Coinfection
Pre or post exposure prophylaxis to
prevent HBV infection. Screening of
blood donor for HBsAg.
 HBV-HDV Superinfection
Education to reduce risk behaviors
among persons with chronic HBV
infection.
Prevention
Hepatitis E
 Hepatitis E is a viral hepatitis (liver inflammation) caused
by infection with a virus called hepatitis E virus (HEV).
 Although Hepatitis E often causes an acute and self-limiting
infection) with low mortality rates.
 In pregnant women the disease is more often severe and is
associated with a clinical syndrome called fulminant hepatic
failure.
 MODE OF TRANSMISSION
 Faecal-oral route
 Contaminated food and water
 Person-person is rare but maternal-neonatal transmission
occur
 Zoonotic spread may occur.
Diagnosis
ELISA kits are available for IgG and IgM
antibodies, using recombinant and synthetic
peptide antigens.
Prevention
Sanitation:
Avoid drinking water of unknown purity,
uncooked shellfish, and uncooked
fruit/vegetables not peeled or prepared by
traveler.
No vaccine currently available.
TREATMENT
No specific treatment
Only supportive measures are required.
Hepatitis G
 GB virus C (GBV-C), formerly known
as hepatitis G virus (HGV) and also known as
HPgV is a virus in the Flaviviridae family and a
member of the Pegivirus genus, is known to
infect humans, but is not known to cause
human disease.
 HGV RNA has been found in patients with
acute, chronic and fulminant hepatitis,
hemophiliacs, patients with multiple
transfusions and hemodialysis, intravenous
drug addicts and blood donors.
34

More Related Content

What's hot

Hepatitis Abc....
Hepatitis Abc....Hepatitis Abc....
Hepatitis Abc....
brian kieth gonzales
 
Hepatitis and cirrhosis
Hepatitis and cirrhosisHepatitis and cirrhosis
Hepatitis and cirrhosis
Dr. Mohamed Maged Kharabish
 
Bohomolets Microbiology Lecture #16
Bohomolets Microbiology Lecture #16Bohomolets Microbiology Lecture #16
Bohomolets Microbiology Lecture #16
Dr. Rubz
 
Hepatitis
HepatitisHepatitis
Hepatitis
OM VERMA
 
Hepatitis acute
Hepatitis acute Hepatitis acute
Hepatitis acute
Jitendra Ingole
 
Hepatitis
HepatitisHepatitis
Hepatitisdorai
 
ACUTE VIRAL HEPATITIS
ACUTE VIRAL HEPATITISACUTE VIRAL HEPATITIS
ACUTE VIRAL HEPATITIS
DrBasith Lateef
 
Viral hepatitis
Viral hepatitisViral hepatitis
Viral hepatitis
MEEQAT HOSPITAL
 
viral hepatitis- types, symptoms, risk factors
viral hepatitis- types, symptoms, risk factors viral hepatitis- types, symptoms, risk factors
viral hepatitis- types, symptoms, risk factors
Raja Rajeswari S
 
Hepatitis virus BACKGROUND, PATHOPHYSIOLOGY AND ETIOLOGY
Hepatitis virus  BACKGROUND, PATHOPHYSIOLOGY AND ETIOLOGYHepatitis virus  BACKGROUND, PATHOPHYSIOLOGY AND ETIOLOGY
Hepatitis virus BACKGROUND, PATHOPHYSIOLOGY AND ETIOLOGY
Devlop Shrestha
 
Chronic hepatitis
Chronic hepatitis Chronic hepatitis
Chronic hepatitis
ikramdr01
 
Acute Hepatitis(pediatrics)
Acute Hepatitis(pediatrics)Acute Hepatitis(pediatrics)
Acute Hepatitis(pediatrics)
Manoj Ghoda
 
Hepatitis
HepatitisHepatitis
Hepatitis ppt
Hepatitis pptHepatitis ppt
Hepatitis ppt
UPUL UDAYARAJ
 
Hepatitis fazil
Hepatitis fazilHepatitis fazil
Hepatitis fazilgokul13
 
Hepatitis
HepatitisHepatitis
Hepatitis
Snigdha Pattnaik
 
Hepatitis
Hepatitis Hepatitis
Hepatitis
Harindu Udapitiya
 

What's hot (20)

Hepatitis Abc....
Hepatitis Abc....Hepatitis Abc....
Hepatitis Abc....
 
Hepatitis and cirrhosis
Hepatitis and cirrhosisHepatitis and cirrhosis
Hepatitis and cirrhosis
 
Bohomolets Microbiology Lecture #16
Bohomolets Microbiology Lecture #16Bohomolets Microbiology Lecture #16
Bohomolets Microbiology Lecture #16
 
Hepatitis
HepatitisHepatitis
Hepatitis
 
Hepatitis acute
Hepatitis acute Hepatitis acute
Hepatitis acute
 
Hepatitis
HepatitisHepatitis
Hepatitis
 
ACUTE VIRAL HEPATITIS
ACUTE VIRAL HEPATITISACUTE VIRAL HEPATITIS
ACUTE VIRAL HEPATITIS
 
Hepatitis
Hepatitis   Hepatitis
Hepatitis
 
Viral hepatitis
Viral hepatitisViral hepatitis
Viral hepatitis
 
viral hepatitis- types, symptoms, risk factors
viral hepatitis- types, symptoms, risk factors viral hepatitis- types, symptoms, risk factors
viral hepatitis- types, symptoms, risk factors
 
Hepatitis virus BACKGROUND, PATHOPHYSIOLOGY AND ETIOLOGY
Hepatitis virus  BACKGROUND, PATHOPHYSIOLOGY AND ETIOLOGYHepatitis virus  BACKGROUND, PATHOPHYSIOLOGY AND ETIOLOGY
Hepatitis virus BACKGROUND, PATHOPHYSIOLOGY AND ETIOLOGY
 
Chronic hepatitis
Chronic hepatitis Chronic hepatitis
Chronic hepatitis
 
Acute Hepatitis(pediatrics)
Acute Hepatitis(pediatrics)Acute Hepatitis(pediatrics)
Acute Hepatitis(pediatrics)
 
Hepatitis
HepatitisHepatitis
Hepatitis
 
Hepatitis ppt
Hepatitis pptHepatitis ppt
Hepatitis ppt
 
Pathology of Hepatitis - Lecture
Pathology of Hepatitis - LecturePathology of Hepatitis - Lecture
Pathology of Hepatitis - Lecture
 
Acute Hepatitisi
Acute HepatitisiAcute Hepatitisi
Acute Hepatitisi
 
Hepatitis fazil
Hepatitis fazilHepatitis fazil
Hepatitis fazil
 
Hepatitis
HepatitisHepatitis
Hepatitis
 
Hepatitis
Hepatitis Hepatitis
Hepatitis
 

Viewers also liked

Chronic hepatits
Chronic hepatitsChronic hepatits
Chronic hepatits
pediatricsmgmcri
 
Liver Chronic Hepatitis
Liver Chronic HepatitisLiver Chronic Hepatitis
Liver Chronic Hepatitis
Rajendran Surendran
 
Chronic hepatitis introduction
Chronic hepatitis introductionChronic hepatitis introduction
Chronic hepatitis introductionAsmaa Eisa
 
Chronic hepatitis
Chronic hepatitisChronic hepatitis
Chronic hepatitis
Ramya Deepthi P
 
Chronic hepatitis
Chronic hepatitisChronic hepatitis
Chronic hepatitis
Naveen Kumar
 
Dr Swati- Case of Hepatomegaly
Dr Swati- Case of HepatomegalyDr Swati- Case of Hepatomegaly
Dr Swati- Case of HepatomegalyAtit Ghoda
 

Viewers also liked (6)

Chronic hepatits
Chronic hepatitsChronic hepatits
Chronic hepatits
 
Liver Chronic Hepatitis
Liver Chronic HepatitisLiver Chronic Hepatitis
Liver Chronic Hepatitis
 
Chronic hepatitis introduction
Chronic hepatitis introductionChronic hepatitis introduction
Chronic hepatitis introduction
 
Chronic hepatitis
Chronic hepatitisChronic hepatitis
Chronic hepatitis
 
Chronic hepatitis
Chronic hepatitisChronic hepatitis
Chronic hepatitis
 
Dr Swati- Case of Hepatomegaly
Dr Swati- Case of HepatomegalyDr Swati- Case of Hepatomegaly
Dr Swati- Case of Hepatomegaly
 

Similar to Swtz seminar

Hepatitis
HepatitisHepatitis
Hepatitisdorai
 
ACUTE HEPATITIS (causes and Clinical Features)
ACUTE HEPATITIS (causes and Clinical Features)ACUTE HEPATITIS (causes and Clinical Features)
ACUTE HEPATITIS (causes and Clinical Features)
faisalali249
 
hepatitis-200829153432 (1).pdf
hepatitis-200829153432 (1).pdfhepatitis-200829153432 (1).pdf
hepatitis-200829153432 (1).pdf
IshikaKakani
 
Viral hepatitis
Viral hepatitis Viral hepatitis
Viral hepatitis
Dr. Saurabh Agrawal
 
Microbiology viral hepatitis and its classificationppt.pptx
Microbiology viral hepatitis and its classificationppt.pptxMicrobiology viral hepatitis and its classificationppt.pptx
Microbiology viral hepatitis and its classificationppt.pptx
Monisha87075
 
3.chronic infection
3.chronic infection3.chronic infection
3.chronic infection
Whiteraven68
 
Hepatitis
HepatitisHepatitis
Hepatitis
HepatitisHepatitis
Viral hepatitis
Viral hepatitisViral hepatitis
Viral hepatitis
Rahul Arya
 
Hepatitis in pediatrics
Hepatitis in pediatricsHepatitis in pediatrics
Hepatitis in pediatrics
Dr Ndayisaba Corneille
 
Viral hepatitis, All types of Hepatitis virus
Viral hepatitis,  All types of Hepatitis virus Viral hepatitis,  All types of Hepatitis virus
Viral hepatitis, All types of Hepatitis virus
RahulDoke4
 
Hepatitis a shivaom
Hepatitis a shivaomHepatitis a shivaom
Hepatitis a shivaom
Shivaom Chaurasia
 
hepatitisnikku-190116054033.pdf
hepatitisnikku-190116054033.pdfhepatitisnikku-190116054033.pdf
hepatitisnikku-190116054033.pdf
LaibaNoor933959
 
Hepatitis
Hepatitis Hepatitis
Hepatitis
Nikhil Vaishnav
 
Liver Disease.ppt
Liver Disease.pptLiver Disease.ppt
Liver Disease.pptShama
 
All types of HEPATITIS IN CHILDREN .pptx
All types of HEPATITIS IN CHILDREN .pptxAll types of HEPATITIS IN CHILDREN .pptx
All types of HEPATITIS IN CHILDREN .pptx
Shibili Abraham
 
Hepat seminar
Hepat seminarHepat seminar
Hepat seminar
Niti Sarawgi
 
Viral hepatitis
Viral hepatitisViral hepatitis
Viral hepatitis
Himanshu Dev
 
Management of Viral Hepatitis in Immunocompromised Patients
Management of Viral Hepatitis in Immunocompromised PatientsManagement of Viral Hepatitis in Immunocompromised Patients
Management of Viral Hepatitis in Immunocompromised Patients
Mohammed A Suwaid
 
NATIONAL GUIDELINES FOR VIRAL HEPATITIS.pptx
NATIONAL GUIDELINES FOR VIRAL HEPATITIS.pptxNATIONAL GUIDELINES FOR VIRAL HEPATITIS.pptx
NATIONAL GUIDELINES FOR VIRAL HEPATITIS.pptx
DrRajatTuteja1
 

Similar to Swtz seminar (20)

Hepatitis
HepatitisHepatitis
Hepatitis
 
ACUTE HEPATITIS (causes and Clinical Features)
ACUTE HEPATITIS (causes and Clinical Features)ACUTE HEPATITIS (causes and Clinical Features)
ACUTE HEPATITIS (causes and Clinical Features)
 
hepatitis-200829153432 (1).pdf
hepatitis-200829153432 (1).pdfhepatitis-200829153432 (1).pdf
hepatitis-200829153432 (1).pdf
 
Viral hepatitis
Viral hepatitis Viral hepatitis
Viral hepatitis
 
Microbiology viral hepatitis and its classificationppt.pptx
Microbiology viral hepatitis and its classificationppt.pptxMicrobiology viral hepatitis and its classificationppt.pptx
Microbiology viral hepatitis and its classificationppt.pptx
 
3.chronic infection
3.chronic infection3.chronic infection
3.chronic infection
 
Hepatitis
HepatitisHepatitis
Hepatitis
 
Hepatitis
HepatitisHepatitis
Hepatitis
 
Viral hepatitis
Viral hepatitisViral hepatitis
Viral hepatitis
 
Hepatitis in pediatrics
Hepatitis in pediatricsHepatitis in pediatrics
Hepatitis in pediatrics
 
Viral hepatitis, All types of Hepatitis virus
Viral hepatitis,  All types of Hepatitis virus Viral hepatitis,  All types of Hepatitis virus
Viral hepatitis, All types of Hepatitis virus
 
Hepatitis a shivaom
Hepatitis a shivaomHepatitis a shivaom
Hepatitis a shivaom
 
hepatitisnikku-190116054033.pdf
hepatitisnikku-190116054033.pdfhepatitisnikku-190116054033.pdf
hepatitisnikku-190116054033.pdf
 
Hepatitis
Hepatitis Hepatitis
Hepatitis
 
Liver Disease.ppt
Liver Disease.pptLiver Disease.ppt
Liver Disease.ppt
 
All types of HEPATITIS IN CHILDREN .pptx
All types of HEPATITIS IN CHILDREN .pptxAll types of HEPATITIS IN CHILDREN .pptx
All types of HEPATITIS IN CHILDREN .pptx
 
Hepat seminar
Hepat seminarHepat seminar
Hepat seminar
 
Viral hepatitis
Viral hepatitisViral hepatitis
Viral hepatitis
 
Management of Viral Hepatitis in Immunocompromised Patients
Management of Viral Hepatitis in Immunocompromised PatientsManagement of Viral Hepatitis in Immunocompromised Patients
Management of Viral Hepatitis in Immunocompromised Patients
 
NATIONAL GUIDELINES FOR VIRAL HEPATITIS.pptx
NATIONAL GUIDELINES FOR VIRAL HEPATITIS.pptxNATIONAL GUIDELINES FOR VIRAL HEPATITIS.pptx
NATIONAL GUIDELINES FOR VIRAL HEPATITIS.pptx
 

Recently uploaded

Introduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp NetworkIntroduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp Network
TechSoup
 
Natural birth techniques - Mrs.Akanksha Trivedi Rama University
Natural birth techniques - Mrs.Akanksha Trivedi Rama UniversityNatural birth techniques - Mrs.Akanksha Trivedi Rama University
Natural birth techniques - Mrs.Akanksha Trivedi Rama University
Akanksha trivedi rama nursing college kanpur.
 
Unit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdfUnit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdf
Thiyagu K
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
Jean Carlos Nunes Paixão
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
camakaiclarkmusic
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
EugeneSaldivar
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
Special education needs
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
DeeptiGupta154
 
Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.
Ashokrao Mane college of Pharmacy Peth-Vadgaon
 
Synthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptxSynthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptx
Pavel ( NSTU)
 
Multithreading_in_C++ - std::thread, race condition
Multithreading_in_C++ - std::thread, race conditionMultithreading_in_C++ - std::thread, race condition
Multithreading_in_C++ - std::thread, race condition
Mohammed Sikander
 
Azure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHatAzure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHat
Scholarhat
 
Digital Artifact 2 - Investigating Pavilion Designs
Digital Artifact 2 - Investigating Pavilion DesignsDigital Artifact 2 - Investigating Pavilion Designs
Digital Artifact 2 - Investigating Pavilion Designs
chanes7
 
Best Digital Marketing Institute In NOIDA
Best Digital Marketing Institute In NOIDABest Digital Marketing Institute In NOIDA
Best Digital Marketing Institute In NOIDA
deeptiverma2406
 
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdfMASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
goswamiyash170123
 
South African Journal of Science: Writing with integrity workshop (2024)
South African Journal of Science: Writing with integrity workshop (2024)South African Journal of Science: Writing with integrity workshop (2024)
South African Journal of Science: Writing with integrity workshop (2024)
Academy of Science of South Africa
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
Sandy Millin
 
How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17
Celine George
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
Balvir Singh
 
Executive Directors Chat Leveraging AI for Diversity, Equity, and Inclusion
Executive Directors Chat  Leveraging AI for Diversity, Equity, and InclusionExecutive Directors Chat  Leveraging AI for Diversity, Equity, and Inclusion
Executive Directors Chat Leveraging AI for Diversity, Equity, and Inclusion
TechSoup
 

Recently uploaded (20)

Introduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp NetworkIntroduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp Network
 
Natural birth techniques - Mrs.Akanksha Trivedi Rama University
Natural birth techniques - Mrs.Akanksha Trivedi Rama UniversityNatural birth techniques - Mrs.Akanksha Trivedi Rama University
Natural birth techniques - Mrs.Akanksha Trivedi Rama University
 
Unit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdfUnit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdf
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
 
Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.
 
Synthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptxSynthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptx
 
Multithreading_in_C++ - std::thread, race condition
Multithreading_in_C++ - std::thread, race conditionMultithreading_in_C++ - std::thread, race condition
Multithreading_in_C++ - std::thread, race condition
 
Azure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHatAzure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHat
 
Digital Artifact 2 - Investigating Pavilion Designs
Digital Artifact 2 - Investigating Pavilion DesignsDigital Artifact 2 - Investigating Pavilion Designs
Digital Artifact 2 - Investigating Pavilion Designs
 
Best Digital Marketing Institute In NOIDA
Best Digital Marketing Institute In NOIDABest Digital Marketing Institute In NOIDA
Best Digital Marketing Institute In NOIDA
 
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdfMASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
 
South African Journal of Science: Writing with integrity workshop (2024)
South African Journal of Science: Writing with integrity workshop (2024)South African Journal of Science: Writing with integrity workshop (2024)
South African Journal of Science: Writing with integrity workshop (2024)
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
 
How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
 
Executive Directors Chat Leveraging AI for Diversity, Equity, and Inclusion
Executive Directors Chat  Leveraging AI for Diversity, Equity, and InclusionExecutive Directors Chat  Leveraging AI for Diversity, Equity, and Inclusion
Executive Directors Chat Leveraging AI for Diversity, Equity, and Inclusion
 

Swtz seminar

  • 2.  Hepatitis is a medical condition defined by the inflammation of the liver and characeterised by the presence of inflammatory cells in the tissue of the organ.  The condition can be self-limiting or can be progress to fibrosis and cirrhosis.
  • 3.  The most common causes of viral hepatitis are the five unrelated hepatotropic viruses Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, and Hepatitis E.  In addition to the nominal hepatitis viruses, other viruses that can also cause liver inflammation include Herpes simplex, Cytomegalovirus, Epstein– Barr virus, or Yellow fever.
  • 4.  DARK URINE  Abdominal discomfort  Right upper abdominal pain  Jaundice  Fever  Nausea  Anorexia  Diaherrea  Fatigue  Hepatomegalin  Elevated level of bilirubin
  • 5.
  • 6.  Hepatitis A (formerly known as “infectious” hepatitis) is an acute infectious disease caused by Hepatitis A virus (HAV).  The disease is heralded by non-specific symptoms such as fever, chills, headache, fatigue, generalized weakness and aches and pains, followed by anorexia, nausea, vomiting, dark urine and jaundice.  The disease is benign with complete recovery in several weeks.
  • 7. Agent factors a) AGENT: The causative agent, the hepatitis A virus, is an enterovirus of the Picornaviridae family. It multiplies only in hepatocytes. b) RESISTANCE: The virus is fairly resistant to heat and chemicals. . RNA Naked RNA virus
  • 8. c) RESERVOIR OF INFECTION: The human cases are the only reservoir of infection. d) INFECTIVE MATERIAL : Mainly man’s faeces. a) AGE: Infection with HAV is more frequent among children than in adults. However, people from all ages may be infected if susceptible. b) SEX: Both sexes are equally susceptible. Host factors
  • 9. Incubation period 10-50 days (usually 25 to 30 days)  Mode of Transmission a) FAECAL-ORAL ROUTE: -By contaminated water, food b) PARENTERAL ROUTE (Rarely): -By blood and blood products or by skin penetration through contaminated needles. c) SEXUAL TRANSMISSION:
  • 10. PHYSICAL EXAMINATION  Icteric sclera,skin and secretions  Mild weight loss of 2-5kg  Hepatomegaly. LABORATORY EXAMINATION 1.Demonstration of Virus in feaces, blood, bile: By: Immunoelectron microscopy 2. Detection of Antibody :By ELISA 4. Biochemical tests: i) Alanine aminotransferase (ALT) ii) Bilirubin
  • 11. Prevention:- -hygienic measures and sanitation -Immunoglobulin to prevent Hepatitis A Immunoglobin provides protection against HAV by passive transfer of conc antibodies against HAV.Ig is effective.preganancy and lactation are not contraindications to receiving Ig.Given iv and im. -vaccines Given as a 2-dose series,6 mnths apart. A vaccine is useful in preventing secondary infection. Treatment: -nospecific, dietary food and long rest Corticosteroid given in patients with acute HAV when cholestic or fulminant hepatic failure is evident.
  • 12.
  • 13. Hepatitis B Hepatitis B (formerly known as “serum” hepatitis) is an acute systemic infection with major pathology in the liver, caused by hepatitis B virus. The acute illness causes liver inflammation, vomiting,jaundice, and, rarely, death. Chronic hepatitis B may eventually cause cirrhosis and liver cancer.
  • 14. Epidemiology Determinants Agent factor a) AGENT: Hepatitis B Virus (HBV) -It replicates in liver cell. b) RESERVOIR OF INFECTION: -Men is the only reservoir of infection which can be spread either from carriers or from cases. c) Infective material: -Contaminated blood is the main source, -Virus has been found in body secretion such as saliva, vaginal secretion & Semen in infected material.
  • 15. • Mode of transmission • Parentral route • Perinatal transmission-spread of infection from HBV carrier mother to their babies.HBV can infect the foetus in utero.This rarely occur at birth,as result of leak of maternal blood into baby’s circulation. • Sexual transmission.
  • 16.  Serology  Liver Chemistry tests AST, ALT, ALP, and total Bilirubin  Histology--Immunoperoxidase staining  Liver Biopsy--to determine grade(Inflammation) and stage(Fibrosis) in chronic Hepatitis
  • 17. Prevention  Vaccination  - highly effective recombinant vaccines  Hepatitis B Immunoglobulin (HBIG)  -exposed within 48 hours of the incident/ neonates whose mothers are HBsAg and HBeAg positive.  Other measures  -screening of blood donors, blood and body fluid precautions.
  • 18. National Immunization Schedule Vaccine When to Give Dose Route Site Hepatitis B At birth or as soon as possible with in 24 hours. 0.5 ml IM Antero lateral side of mid thigh Hepatitis B 1,2,3 At 6, 10, 14 weeks 0.5 ml IM Antero lateral side of mid thigh
  • 19. TREATMENT FOR HEPATITIS B? Alpha interferon and peginterferon, which slow the replication of the virus in the body and also boost the immune system, and the antiviral drugs lamivudine, adefovir,, entecavir.
  • 20.
  • 21. Hepatitis C  Hepatitis C is an infectious disease affecting primarily the liver, caused by the hepatitis C virus (HCV).  The infection is often asymptomatic, but chronic infection can lead to scarring of the liver and ultimately to cirrhosis, which is generally apparent after many years.
  • 22. Incubation Period 40-120 days Mode of Transmission  Intravenous Drug Use  Healthcare Exposure: Blood Transfusion, transfusion of Blood products, Organ Transplant without HCV screening carry significant risk of infection.  Hemodialysis  Accidental injuries with needles/sharps  Multiple sex partners  Vertical Transmission: Vertical transmission of hepatitis C from an infected mother to her child.
  • 23. • HCV antibody – ELISA used to diagnose hepatitis C infection. Not useful in the acute phase as it takes at least 4 weeks after infection before antibody appears. • HCV-RNA - various techniques are available e.g. PCR and branched DNA. May be used to diagnose HCV infection in the acute phase. However, its main use is in monitoring the response to antiviral therapy. • HCV-antigen - It is used in the same capacity as HCV-RNA tests but is much easier to carry out. Diagnosis
  • 24. Prevention  Only General Prophylaxis, such as blood, tissue, organ screening, is possible.  No specific active or passive immunizing agent is available. Treatment  Interferon - may be considered for patients with chronic active hepatitis.  Ribavirin - combination of interferon and ribavirin is more effective than interferon alone.
  • 25.
  • 26. Hepatitis D  Hepatitis D, also referred to as hepatitis D virus (HDV) and classified as Hepatitis delta virus, is a disease caused by a small circular enveloped RNA virus.  HDV infection develops only in patients who are positive for hepatitis B surface antigen. Incubation Period 2-12weeks The primary route of Transmission are believed to be similar to those of HBV, It can be transmitted sexually..perinatal transmission is rare.  Mode of Transmission
  • 27.  HDV replicates only in liver cell and so the cellular damage associated with HDV infection involves mainly in liver.  HDV co-infection with HBV may be associated with increased risk of severe clinical hepatitis,fulminant hepatic failure,chronic liver disease,cirrhosis and hepatocellular carcinoma.
  • 28. Diagnosis  Delta antigen is primarily expressed in liver cell nuclei, where it can be demonstrated by immunofluorescence.  Anti-delta antibodies appear in serum and can be identified by ELISA. IgM antibody appears 2-3 weeks after infection and is soon replaced by the IgG antibody in acute delta infection. TREATMENT  Interferon  Lamivudine  Adefovir
  • 29.  HBV-HDV Coinfection Pre or post exposure prophylaxis to prevent HBV infection. Screening of blood donor for HBsAg.  HBV-HDV Superinfection Education to reduce risk behaviors among persons with chronic HBV infection. Prevention
  • 30.
  • 31. Hepatitis E  Hepatitis E is a viral hepatitis (liver inflammation) caused by infection with a virus called hepatitis E virus (HEV).  Although Hepatitis E often causes an acute and self-limiting infection) with low mortality rates.  In pregnant women the disease is more often severe and is associated with a clinical syndrome called fulminant hepatic failure.  MODE OF TRANSMISSION  Faecal-oral route  Contaminated food and water  Person-person is rare but maternal-neonatal transmission occur  Zoonotic spread may occur.
  • 32. Diagnosis ELISA kits are available for IgG and IgM antibodies, using recombinant and synthetic peptide antigens. Prevention Sanitation: Avoid drinking water of unknown purity, uncooked shellfish, and uncooked fruit/vegetables not peeled or prepared by traveler. No vaccine currently available. TREATMENT No specific treatment Only supportive measures are required.
  • 33. Hepatitis G  GB virus C (GBV-C), formerly known as hepatitis G virus (HGV) and also known as HPgV is a virus in the Flaviviridae family and a member of the Pegivirus genus, is known to infect humans, but is not known to cause human disease.  HGV RNA has been found in patients with acute, chronic and fulminant hepatitis, hemophiliacs, patients with multiple transfusions and hemodialysis, intravenous drug addicts and blood donors.
  • 34. 34